Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®

Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, announced a worldwide licensing agreement with OcuNexus Therapeutics for NEXAGON®, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care.

NEXAGON, is a first in class unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43).

Recently, Eyevance acquired exclusive rights to market and commercialize ZERVIATE™ (cetirizine ophthalmic solution) 0.24% within the United States from Nicox, Inc. and FRESHKOTE^® – a family of preservative free lubricant eye drops from Focus Laboratories, Inc.